Cancer Immunotherapy Equipment For Medical Specialties
-
Manufactured by Inovarionbased in FRANCE
The latest advances in cancerology have made it possible to dissect the complexity of the signaling pathways leading to cancerous pathologies. New lines of thought have thus been drawn up in terms of therapies and tumor characterization. The mechanisms of oncogenesis, resistance to treatments and the identification of diagnostic biomarkers are major areas of research. Our teams can intervene on a ...
-
Manufactured by ACROBiosystemsbased in USA
IL-15,Interleukin-15,IL15,Interleukin ...
-
Manufactured by Promega Corporationbased in USA
4-1BB (CD137/TNFRSF9), a member of the tumor necrosis factor receptor superfamily, is an inducible co-stimulatory receptor expressed on T cells, natural killer (NK) cells and innate immune cell populations. When present on the cell surface, 4-1BB interacts with 4-1BB ligand (4-1BBL) and induces subsequent cell proliferation and production of interferon gamma (IFNγ) and interleukin-2 (IL-2), ...
-
based in AUSTRALIA
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen ...
-
Manufactured by Ativa Medicalbased in USA
Ativa's Diagnostic Workstation with a miniaturized flow-cytometer can measure the innate immune response cells in the blood. In COVID-19, Natural-Killer Cell activation occurs within hours of first infection, these cells fight the Virus in the lungs. Miniaturized low-cost diagnostic tests Immediate lab-quality results Advanced A.I. disease screening …all at the patient ...
-
based in AUSTRIA
The high level of interferon induced by the delNS vector activates immunological defence reactions against cancer. It also stimulates the production of antiviral ...
-
Manufactured by OSE Immunotherapeuticsbased in FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
-
Manufactured by Cartherics Pty ltdbased in AUSTRALIA
This technology involves induced pluripotential stem cell (iPSC) derived NK cells (and, potentially, other types of immune cells). iPSCs have unlimited capacity for ...
-
Manufactured by Mablink Biosciencebased in FRANCE
Antibody–drug conjugates (ADCs) are a unique class of targeted immuno-oncology therapeutics that combine the tumor-targeting selectivity, stability, and favorable pharmacokinetic profile of monoclonal antibodies, with the potent antitumor activity of cytotoxic drugs. The ultimate goal of ADCs is to increase the therapeutic index of potent chemical agents, by the selective delivery of the ...
-
Manufactured by Scopus BioPharmabased in USA
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the activity of the STAT3 gene by way of RNA interference. CO-sTiRNA™ also stimulates TLR9 receptors to activate the body’s immune defense to ...
-
based in USA
Innovators in immunotherapy, stem cell therapy, and regenerative medicine will find like-minded champions at ...
-
Manufactured by Kiadis Pharma NVbased in NETHERLANDS
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases.1 Today, we ...
-
Manufactured by Tempusbased in USA
648 gene panel + Whole transcriptome RNA sequencing with validated fusion detection, Enriched for clinically relevant genes and genes of emerging clinical relevance, Immunotherapy Metrics: MSI Status, Tumor Mutational Burden (TMB), IHC Options: Mismatch Repair (MMR), PD-L1 (22C3, SP142, and 28-8 clones), Available Add-on Tests: Tumor Origin (TO), Homologous Recombination Deficiency (HRD), DPYD ...
-
based in USA
Influenza (Target age 65+) and Influenza+ SARS-C0V-2 ...
-
Manufactured by Transgenebased in FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
-
Manufactured by BioFactura, Inc.based in USA
BioFactura is developing a Marburg therapeutic in close collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Marburg virus (MARV) was first described in 1967 as the causative agent of a hemorrhagic fever illness that occurred in laboratory workers at a primate facility in Germany and Yugoslavia. Since its discovery, marburgviruses have caused at ...
-
Manufactured by Biomatik Corporationbased in CANADA
Species:Homo sapiens (Human). Source:E.coli. Tag Info:N-terminal His Tag. Biological Activity:Not tested. Covid-19: ...
-
Manufactured by Fate Therapeutics, Inc.based in USA
NK cells play a major role in the anti-tumor efficacy of certain tumor-antigen targeting antibodies. NK cells express CD16, an activating receptor that binds to the Fc portion of IgG antibodies. Once activated through CD16, NK cells are able to destroy antibody-coated target cells and secrete cytokines, such as interferon gamma, to recruit and potentiate adaptive immune cells, including T cells. ...
-
Manufactured by Context Therapeutics Inc.based in USA
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many solid tumor types, including ovarian, endometrial, ...
-
Manufactured by ORYX GmbH & Co. KGbased in GERMANY
Several cancers arise from the lack of DNA mismatch repair (MMR) resulting in the accumulation of thousands of single deletions or insertions at coding microsatellites (MSI-H). These mutations lead to the inactivation of specific proteins and to the expression of frameshift peptides (FSPs). These FSPs are tumor-specific antigens, which are constantly expressed. Cancers with MSI-H mutations ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you